ERNA

SEC source: 0001140361-24-023012 · form4.xml · derivative · entry 1

Gurrola Sandra M · CIK 0001618457 · Sr. VP of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2034-04-26

F1 · derivative.exercise_date: The stock option shall vest in an initial installment of one-third on the one-year anniversary of the grant date, and the remaining shares shall vest in 24 substantially equal monthly installments thereafter.

SEC source: 0001140361-24-023013 · form4.xml · derivative · entry 1

Cicala Peter · CIK 0002011534 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,946

Underlying: Common Stock · 88,946 shares

Expires 2034-04-26

F1 · derivative.exercise_date: The stock option shall vest as to 100% of the number of shares subject to the stock option on the one-year anniversary of the grant date.

SEC source: 0001140361-24-023011 · form4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,525

Underlying: Common Stock · 124,525 shares

Expires 2034-04-26

F1 · derivative.exercise_date: The stock option shall vest as to 100% of the number of shares subject to the stock option on the one-year anniversary of the grant date.

SEC source: 0001140361-24-000469 · form4.xml · derivative · entry 1

Luther Sanjeev · CIK 0001933592 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,685,218

Underlying: Common Stock, par value $0.005 per share · 1,685,218 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Subject to continued service, 25% of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 36 substantially equal monthly installments thereafter.

SEC source: 0001140361-24-000468 · form4.xml · derivative · entry 1

Clarke Dorothy J · CIK 0001992152 · Director · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,521

Underlying: Common Stock, par value $0.005 per share · 168,521 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Subject to continued service, 25% of the shares underlying the stock option will vest on the nine-month anniversary of the grant date, and the remaining shares underlying the stock option will vest in 39 substantially equal monthly installments thereafter.

SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 6

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,991,394

Underlying: Common Stock, par value $0.005 per share · 1,041,992 shares

Expires 2028-12-15

F3 · price: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4 · price: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 5

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 783,233

Underlying: Common Stock, par value $0.005 per share · 520,996 shares

Expires 2028-12-15

F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 4

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 949,402

Underlying: Common Stock, par value $0.005 per share · 524,474 shares

Expires 2028-07-14

F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 3

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 424,928

Underlying: Common Stock, par value $0.005 per share · 524,474 shares

Expires 2028-07-14

F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 2

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 949,402

Underlying: Common Stock, par value $0.005 per share · 424,928 shares

Expires 2028-06-02

F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 1

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 524,474

Underlying: Common Stock, par value $0.005 per share · 424,928 shares

Expires 2028-06-02

F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

SEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 6

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 523,512

Underlying: Common Stock · 523,512 shares

Expires 2028-06-02

F5 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on December 2, 2022 to reduce the exercise price from $3.28 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

SEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 5

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 523,512 shares

Expires 2028-06-02

F5 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on December 2, 2022 to reduce the exercise price from $3.28 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

SEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 4

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,307,692

Underlying: Common Stock · 2,307,692 shares

Expires 2028-07-14

F4 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on July 14, 2023 to reduce the exercise price from $2.61 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

SEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 3

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,307,692 shares

Expires 2028-07-14

F4 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on July 14, 2023 to reduce the exercise price from $2.61 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

SEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 2

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,125,976

Underlying: Common Stock · 3,125,976 shares

Expires 2028-12-15

F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the "Notes") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $1.43 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules.

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the "Notes") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $1.43 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules.

F3 · derivative.underlying_shares: The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation.

SEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 1

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 1,562,988 shares

Expires 2028-12-15

F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the "Notes") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $1.43 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules.

F2 · derivative.underlying_shares: The conversion of the Notes is subject to a 19.99% beneficial ownership limitation.

SEC source: 0000899243-23-017414 · doc4.xml · derivative · entry 2

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 949,402

Underlying: Common Stock, par value $0.005 per share · 524,474 shares

Expires 2028-07-14

F2 · price: On July 13, 2023, Freebird Partners entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $750,000, (i) a Senior Convertible Note in the principal amount of $750,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 524,474 shares of Common Stock (the "Warrant" and such transactions the "Transactions". The Transactions closed on July 14, 2023. The Note may be converted at any time and from time to time after July 14, 2023, at the option of the holder, at a conversion price of $2.86 per share of Common Stock. The Warrant becomes exercisable on July 14, 2023, and may be exercised through July 14, 2028, at an exercise price of $2.61 per share of Common Stock.

F1 · ownership.direct: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F2 · ownership.direct: On July 13, 2023, Freebird Partners entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $750,000, (i) a Senior Convertible Note in the principal amount of $750,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 524,474 shares of Common Stock (the "Warrant" and such transactions the "Transactions". The Transactions closed on July 14, 2023. The Note may be converted at any time and from time to time after July 14, 2023, at the option of the holder, at a conversion price of $2.86 per share of Common Stock. The Warrant becomes exercisable on July 14, 2023, and may be exercised through July 14, 2028, at an exercise price of $2.61 per share of Common Stock.

SEC source: 0000899243-23-017414 · doc4.xml · derivative · entry 1

Freebird Partners LP · CIK 0001955231 · 10% owner

Freebird Investments LLC · CIK 0001971406 · 10% owner

HUFF CURTIS W · CIK 0001250127 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,237

Underlying: Common Stock, par value $0.005 per share · 262,237 shares

Expires 2028-07-14

F1 · ownership.direct: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F2 · ownership.direct: On July 13, 2023, Freebird Partners entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $750,000, (i) a Senior Convertible Note in the principal amount of $750,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 524,474 shares of Common Stock (the "Warrant" and such transactions the "Transactions". The Transactions closed on July 14, 2023. The Note may be converted at any time and from time to time after July 14, 2023, at the option of the holder, at a conversion price of $2.86 per share of Common Stock. The Warrant becomes exercisable on July 14, 2023, and may be exercised through July 14, 2028, at an exercise price of $2.61 per share of Common Stock.

SEC source: 0001140361-23-034995 · form4.xml · derivative · entry 2

BINDER BRANT · CIK 0001133594 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,916

Underlying: Common Stock · 83,916 shares

Expires 2028-07-14

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.

SEC source: 0001140361-23-034995 · form4.xml · derivative · entry 1

BINDER BRANT · CIK 0001133594 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 41,958 shares

Expires 2028-07-14

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.

SEC source: 0001140361-23-034994 · form4.xml · derivative · entry 2

WAGNER RICHARD W · CIK 0001277280 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,916

Underlying: Common Stock · 83,916 shares

Expires 2028-07-14

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.

SEC source: 0001140361-23-034994 · form4.xml · derivative · entry 1

WAGNER RICHARD W · CIK 0001277280 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 41,958 shares

Expires 2028-07-14

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.

SEC source: 0001104659-23-095434 · tm2323568-3_4seq1.xml · derivative · entry 2

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,307,692

Underlying: Common Stock · 2,307,692 shares

Expires 2028-07-14

F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules.

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules.

F3 · derivative.underlying_shares: The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation.

SEC source: 0001104659-23-095434 · tm2323568-3_4seq1.xml · derivative · entry 1

Cherington Charles · CIK 0001448698 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 1,153,846 shares

Expires 2028-07-14

F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules.

F2 · derivative.underlying_shares: The conversion of the Notes is subject to a 19.99% beneficial ownership limitation.

SEC source: 0001140361-23-031258 · form4.xml · derivative · entry 3

Gurrola Sandra M · CIK 0001618457 · Vice President of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 874

Underlying: Common Stock · 438 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock.

F2 · derivative.exercise_date: On June 21, 2021, the reporting person was granted 1,750 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: On June 21, 2021, the reporting person was granted 1,750 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

SEC source: 0001140361-23-031258 · form4.xml · nonDerivative · entry 2

Gurrola Sandra M · CIK 0001618457 · Vice President of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 928

SEC source: 0001140361-23-031258 · form4.xml · nonDerivative · entry 1

Gurrola Sandra M · CIK 0001618457 · Vice President of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit converts into one share of common stock.

SEC source: 0001140361-23-001698 · form4.xml · derivative · entry 1

Angel Matthew · CIK 0001931356 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,003

Underlying: Common Stock, par value $0.005 per share · 132,003 shares

Expires 2033-01-12

F1 · derivative.exercise_date: The stock options vests and becomes exercisable over three years (subject to continued service), with 110,043 of the shares vesting on the grant date, and the remaining shares vesting in 36 substantially equal monthly tranches on the first day of each month thereafter.

SEC source: 0001062993-22-023351 · form4.xml · derivative · entry 3

HALPERN JOHN D · CIK 0001234950 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · As trustee of family trust

Disclosed balance after: 671,840

Underlying: Common Stock · 671,840 shares

Expires 2028-12-02

F5 · shares: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.

F5 · derivative.underlying_shares: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.

F5 · balance_after: The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.

F4 · ownership.nature: The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-22-023351 · form4.xml · nonDerivative · entry 2

HALPERN JOHN D · CIK 0001234950 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · As trustee of family trust

Disclosed balance after: 450,961

F3 · price: Each share was purchased as part of a unit consisting of one share and two warrants, for a total purchase price of $3.53 per unit.

F1 · balance_after: Reflects a 1-for-20 reverse stock split effective October 17, 2022.

F4 · ownership.nature: The reporting persons disclaim beneficial ownership of these shares except to the extent of their pecuniary interest therein, if any.

SEC source: 0001140361-22-044639 · form4.xml · derivative · entry 2

Cherington Charles · CIK 0001448698 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523,512

Underlying: Common Stock, par value $0.005 per share · 523,512 shares

Expires 2028-06-02

F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

SEC source: 0001140361-22-044639 · form4.xml · nonDerivative · entry 1

Cherington Charles · CIK 0001448698 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 556,465

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

SEC source: 0001140361-22-044631 · form4.xml · derivative · entry 4

Singer Nicholas Jason · CIK 0001828224 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pacific Premier Trust, Custodian, FBO Nicholas J. Singer

Disclosed balance after: 424,928

Underlying: Common Stock, par value $0.005 per share · 424,928 shares

Expires 2028-06-02

F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 283,286 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 283,286 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

SEC source: 0001140361-22-044631 · form4.xml · derivative · entry 3

Singer Nicholas Jason · CIK 0001828224 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Purchase Capital LLC

Disclosed balance after: 141,644

Underlying: Common Stock, par value $0.005 per share · 141,644 shares

Expires 2028-06-02

F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 283,286 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 283,286 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

SEC source: 0001140361-22-044631 · form4.xml · nonDerivative · entry 2

Singer Nicholas Jason · CIK 0001828224 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pacific Premier Trust, Custodian, FBO Nicholas J. Singer

Disclosed balance after: 266,214

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 283,286 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

SEC source: 0001140361-22-044631 · form4.xml · nonDerivative · entry 1

Singer Nicholas Jason · CIK 0001828224 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Purchase Capital LLC

Disclosed balance after: 121,822

F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 283,286 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules.

SEC source: 0001140361-22-034312 · form4.xml · derivative · entry 2

Sidhu Roger · CIK 0001884115 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,487

Underlying: Common Stock · 20,163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock.

F2 · derivative.exercise_date: On September, 2021, the reporting person was granted 80,650 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: On September, 2021, the reporting person was granted 80,650 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.

SEC source: 0001140361-22-034312 · form4.xml · nonDerivative · entry 1

Sidhu Roger · CIK 0001884115 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,163

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit converts into one share of common stock.

SEC source: 0001140361-22-028096 · form4.xml · derivative · entry 1

Angel Matthew · CIK 0001931356 · Director · Interim President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,487,003

Underlying: Common Stock, par value $0.005 per share · 2,487,003 shares

Expires 2032-08-01

F1 · derivative.exercise_date: The stock option vests and becomes exercisable over four years (subject to continued service), with 2/48th of the shares vesting on the grant date and the remaining shares vesting in 46 substantially equal monthly installments thereafter.

SEC source: 0001140361-22-028095 · form4.xml · derivative · entry 2

Cherington Charles · CIK 0001448698 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,800

Underlying: Common Stock, par value $0.005 per share · 165,800 shares

Expires 2032-08-01

F2 · derivative.exercise_date: The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001140361-22-028095 · form4.xml · derivative · entry 1

Cherington Charles · CIK 0001448698 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,100

Underlying: Common Stock, par value $0.005 per share · 215,100 shares

Expires 2032-08-01

F1 · derivative.exercise_date: The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.

SEC source: 0001140361-22-028094 · form4.xml · derivative · entry 2

Fiore Gregory · CIK 0001931959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,800

Underlying: Common Stock, par value $0.005 per share · 165,800 shares

Expires 2032-08-01

F2 · derivative.exercise_date: The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001140361-22-028094 · form4.xml · derivative · entry 1

Fiore Gregory · CIK 0001931959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,100

Underlying: Common Stock, par value $0.005 per share · 95,100 shares

Expires 2032-08-01

F1 · derivative.exercise_date: The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.

SEC source: 0001140361-22-028097 · form4.xml · derivative · entry 2

Wexler William A. · CIK 0001927975 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,800

Underlying: Common Stock, par value $0.005 per share · 165,800 shares

Expires 2032-08-01

F2 · derivative.exercise_date: The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001140361-22-028097 · form4.xml · derivative · entry 1

Wexler William A. · CIK 0001927975 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,100

Underlying: Common Stock, par value $0.005 per share · 152,100 shares

Expires 2032-08-01

F1 · derivative.exercise_date: The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.

SEC source: 0001140361-22-028093 · form4.xml · derivative · entry 2

Singer Nicholas Jason · CIK 0001828224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,800

Underlying: Common Stock, par value $0.005 per share · 165,800 shares

Expires 2032-08-01

F2 · derivative.exercise_date: The stock option vests and becomes exercisable over two years (subject to continued service), with 1/3 of the shares vesting on the grant date and the remaining shares vesting in 24 substantially equal monthly installments thereafter.

SEC source: 0001140361-22-028093 · form4.xml · derivative · entry 1

Singer Nicholas Jason · CIK 0001828224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,100

Underlying: Common Stock, par value $0.005 per share · 146,100 shares

Expires 2032-08-01

F1 · derivative.exercise_date: The stock option vests and becomes exercisable over one year (subject to continued service), with 25% of the shares vesting every three months from the grant date.

SEC source: 0001140361-22-024524 · form4.xml · derivative · entry 3

DAmour Kevin · CIK 0001870486 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,717

Underlying: Common Stock · 17,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock.

F2 · derivative.exercise_date: On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.

SEC source: 0001140361-22-024524 · form4.xml · nonDerivative · entry 2

DAmour Kevin · CIK 0001870486 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,496